Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Why Portola couldn’t flex its muscles or use them yet

August 9, 2018 0

All the buying and selling of Portola (PTLA) will not make any sense to us until the …

Spark Therapeutics: A usual reaction to SPK-8011 results should have been a celebration

August 8, 2018 0

When an investigational gene therapy gets excellent results, the usual reaction towards the developing firm is …

Exelixis: Why Q2 results are more than impressive

August 2, 2018 0

Exciting are the Q2 2018 reported results by Exelixis’ (EXEL) including the firm’s revenues and earnings, …

Victims of fear and misunderstanding

August 1, 2018 0

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …

A new European approval for Bristol-Myers’ immunotherapy opdivo. The future is starting now

July 31, 2018 0

The Future is Starting Now Recognizing that the future has already started now is important as …

The EU CHMP Recommends Approving Alnylam’s RNAi Therapeutic, ONPATTRO™

July 27, 2018 0

The Committee for Medicinal Products for Human Use (CHMP) announced a Positive Opinion recommending marketing authorization of Alnylam’s …

The FDA approved Neurocrine’s & AbbVie’s Endometriosis drug, Orilissa. Neurocrine stock met & surpassed the Prohost 2018 target

July 25, 2018 0

AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced that the United States FDA approved …

Biogen’s Exciting Q2 Results Highlighted Ionis (IONS) Too

July 24, 2018 0

The good news from Biogen’s (BIIB) Q2 exciting financial results comprised impressive news for Ionis (IONS) …

About PTC Therapeutics’ Acquisition of Agilis Biotherapeutics

July 20, 2018 0

Yesterday’s news unveiled that PTC Therapeutics (PTCT) has entered into an agreement to acquire Agilis Biotherapeutics. The …

Novartis Pleased the Market with Its Q2 Financial Results and Pleased Us with Its Great Scientific Achievements. See Also: The Role AveXis and RegenxBio are Playing Towards the Future Success of Novartis

July 19, 2018 0

Novartis’ (NVS) financials results exceeded analysts’ expectations. The firm’s research institutions’ strategy, well-designed structure, plans for …

Once again, we say, CRISPR is here to stay

July 18, 2018 0

A Miracle-Like Gene-Editing That People will Sooner or Later Recognize. The Wellcome Sanger Institute’s new findings …

$Amgen and UCB resubmit BLA to the FDA for the approval of Evenity™ to prevent or heal Osteoporosis bone fracture in post-menopausal women$

Amgen and UCB resubmit BLA to the FDA for the approval of Evenity™ to prevent or heal Osteoporosis bone fracture in post-menopausal women

July 13, 2018 0

The BLA Includes Data from More Than 11,000 Patients Amgen (AMGN) and UCB (Euronext Brussels: UCB) …

Stories about research, clinical trials results and an FDA ruling

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Why Portola couldn’t flex its muscles or use them yet

Spark Therapeutics: A usual reaction to SPK-8011 results should have been a celebration

Exelixis: Why Q2 results are more than impressive

Victims of fear and misunderstanding

A new European approval for Bristol-Myers’ immunotherapy opdivo. The future is starting now

The EU CHMP Recommends Approving Alnylam’s RNAi Therapeutic, ONPATTRO™

The FDA approved Neurocrine’s & AbbVie’s Endometriosis drug, Orilissa. Neurocrine stock met & surpassed the Prohost 2018 target

Biogen’s Exciting Q2 Results Highlighted Ionis (IONS) Too

About PTC Therapeutics’ Acquisition of Agilis Biotherapeutics

Novartis Pleased the Market with Its Q2 Financial Results and Pleased Us with Its Great Scientific Achievements. See Also: The Role AveXis and RegenxBio are Playing Towards the Future Success of Novartis

Once again, we say, CRISPR is here to stay

Amgen and UCB resubmit BLA to the FDA for the approval of Evenity™ to prevent or heal Osteoporosis bone fracture in post-menopausal women

Stories about research, clinical trials results and an FDA ruling

Exelixis liver cancer results are gratifying, so do not worry if some pretend they do not like them

The FDA Clears Compugen’s and Bayer’s IND Application for Their Checkpoint Inhibitor Immunotherapy Product

Finding reasons for underperforming stocks

Why Vertex added over $20 to its stock price today

The FDA approved a combination of two products. Both belong to Array Biopharma

Exploring two clinical-stage firms with new, different approaches to treatments

Our outperforming firms and more